Literature DB >> 23292660

Personalized medicine of type 2 diabetes.

Weiping Jia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23292660     DOI： 10.1007/s11684-013-0241-y

Source DB:  PubMed          Journal:  Front Med        ISSN： 2095-0217            Impact factor:   4.592


× No keyword cloud information.
  12 in total

Review 1.  Clinical practice. Glycemic management of type 2 diabetes mellitus.

Authors:  Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

2.  Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes.

Authors:  W Yu; C Hu; R Zhang; C Wang; W Qin; J Lu; F Jiang; S Tang; Y Bao; K Xiang; W Jia
Journal:  Clin Pharmacol Ther       Date:  2011-02-02       Impact factor: 6.875

Review 3.  Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.

Authors:  Vangelis G Manolopoulos; Georgia Ragia; Anna Tavridou
Journal:  Pharmacogenomics       Date:  2011-08       Impact factor: 2.533

4.  IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population.

Authors:  Qiong Huang; Ji-ye Yin; Xing-ping Dai; Qi Pei; Min Dong; Zhi-guang Zhou; Xi Huang; Min Yu; Hong-hao Zhou; Zhao-qian Liu
Journal:  Acta Pharmacol Sin       Date:  2010-06       Impact factor: 6.150

5.  Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.

Authors:  Ewan R Pearson; Isabelle Flechtner; Pål R Njølstad; Maciej T Malecki; Sarah E Flanagan; Brian Larkin; Frances M Ashcroft; Iwar Klimes; Ethel Codner; Violeta Iotova; Annabelle S Slingerland; Julian Shield; Jean-Jacques Robert; Jens J Holst; Penny M Clark; Sian Ellard; Oddmund Søvik; Michel Polak; Andrew T Hattersley
Journal:  N Engl J Med       Date:  2006-08-03       Impact factor: 91.245

6.  Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know.

Authors:  Robert J Smith; David M Nathan; Silva A Arslanian; Leif Groop; Robert A Rizza; Jerome I Rotter
Journal:  J Clin Endocrinol Metab       Date:  2010-03-01       Impact factor: 5.958

7.  Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.

Authors:  Amnon Zung; Benjamin Glaser; Revital Nimri; Zvi Zadik
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

Review 8.  Pharmacogenomics and individualized drug therapy.

Authors:  Michel Eichelbaum; Magnus Ingelman-Sundberg; William E Evans
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

9.  Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients.

Authors:  Qiong Huang; Ji-Ye Yin; Xing-Ping Dai; Jing Wu; Xiang Chen; Cai-Shu Deng; Min Yu; Zhi-Cheng Gong; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Eur J Clin Pharmacol       Date:  2010-08-31       Impact factor: 2.953

10.  Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients.

Authors:  Ya-yi He; Rong Zhang; Xin-yu Shao; Cheng Hu; Cong-rong Wang; Jun-xi Lu; Yu-qian Bao; Wei-ping Jia; Kun-san Xiang
Journal:  Acta Pharmacol Sin       Date:  2008-08       Impact factor: 6.150
View more
  2 in total

1.  Words matter: distinguishing "personalized medicine" and "biologically personalized therapeutics".

Authors:  Nathan I Cherny; Elisabeth G E de Vries; Linda Emanuel; Lesley Fallowfield; Prudence A Francis; Alberto Gabizon; Martine J Piccart; David Sidransky; Lior Soussan-Gutman; Chariklia Tziraki
Journal:  J Natl Cancer Inst       Date:  2014-10-07       Impact factor: 13.506

2.  Joint effects of diabetic-related genomic loci on the therapeutic efficacy of oral anti-diabetic drugs in Chinese type 2 diabetes patients.

Authors:  Miao Chen; Rong Zhang; Feng Jiang; Jie Wang; Danfeng Peng; Jing Yan; Shiyun Wang; Tao Wang; Yuqian Bao; Cheng Hu; Weiping Jia
Journal:  Sci Rep       Date:  2016-03-17       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.